Cantor keeps USD 22.00 target for Omeros stock

Published on 10/24/2026 at 19:03 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Cantor Fitzgerald kept its Overweight view on October 14, 2026. Omeros stock costs EUR 14.80 on October 24, 2026 at Lang & Schwarz.

Analyst target and earnings date

Cantor Fitzgerald maintained its USD 22.00 target and Overweight rating on October 14, 2026.
Omeros reported USD 28.53 million in second-quarter 2026 revenue against USD 12.67 million of estimates.
Omeros stock stood at EUR 14.80 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
Omeros is scheduled to report earnings on November 12, 2026.

OMER, US6821431029, Illustration mit AI erstellt.

Omeros Corporation (ISIN US6821431029) remains tied to Cantor Fitzgerald's USD 22.00 price target and Overweight rating, reaffirmed on October 14, 2026, according to Investing.com. Omeros stock stood at EUR 14.80 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.

Target remains above Nasdaq price

The Cantor target was unchanged at USD 22.00, while the Nasdaq last traded at USD 16.57 on October 23, 2026 at 4:00 p.m. ET. The target therefore stood 32.77 percent above the Nasdaq price, a gap that keeps the analyst view central to the valuation discussion.

Omeros' second-quarter 2026 revenue reached USD 28.53 million, compared with USD 12.67 million of consensus estimates, according to Investing.com. The same report said adjusted earnings reached USD 0.02 per share against an expected loss of USD 0.25 per share. The revenue comparison amounts to a 125.50 percent beat over the estimate.

Price position and upcoming date

The Nasdaq price of USD 16.57 was 21.99 percent below Omeros' 52-week high of USD 21.24 and 165.54 percent above its 52-week low of USD 6.24 on October 23, 2026. Trading volume was 698,891 shares, against average volume of 1,708,026 shares. Market capitalization stood at USD 1.2 billion on that date.

Yahoo Finance lists November 12, 2026 as Omeros' next earnings date. The company develops commercial and investigational therapies for immune and rare diseases, with Yartemlea among its marketed products.

Comparison with peers

Omeros: Nasdaq, USD, last price USD 16.57, trailing P/E 13.58, market capitalization USD 1.2 billion on October 23, 2026.

Regeneron Pharmaceuticals: Nasdaq, USD, down 1.72 percent, P/E 19.91, market capitalization USD 82.9 billion on October 23, 2026.

Vertex Pharmaceuticals: Nasdaq, USD, down 2.10 percent, P/E 30.50, market capitalization USD 132.8 billion on October 23, 2026.

What the target means for valuation

Cantor's USD 22.00 target sits above both Omeros' Nasdaq price and the company's current 52-week midpoint of USD 13.74. The upcoming November 12 earnings date gives investors the next scheduled point for testing revenue momentum and profitability.

The further course of trading is shown by the continuously updated real-time quote of Omeros stock.